Wegovy vs Ozempic

Though they share the same active ingredients, Wegovy and Ozempic share some differences. Many of these are related to how they’re used, doses and FDA approvals.

Approved uses

Ozempic and Wegovy have multiple approved uses. The FDA has approved Wegovy for chronic weight loss management to treat obesity and reduce the risk of certain cardiovascular diseases and events. Ozempic is also approved for the treatment of type 2 diabetes.

The FDA first approved Ozempic to reduce cardiovascular risk and manage blood glucose levels in patients with type 2 diabetes in December 2017. It’s generally administered as a weekly injection. Though Ozempic isn’t approved for weight loss, many physicians have also been prescribing this semaglutide drug as a weight-loss drug.

In June 2021, the FDA approved Wegovy for weight loss in adults who are obese or overweight with at least one weight-related health condition.

Cost and insurance coverage for Wegovy and Ozempic

During U.S. Senate committee meetings held in September 2024, federal lawmakers explained that Wegovy could cost as much as $1,349 per month, with Ozempic listed at $969 per month at that time.

Like most prescription medications, costs can vary depending on your insurance coverage. As of December 2025, the manufacturer’s list prices are:

• Wegovy: $1,350 for a 28-day supply
• Ozempic:  $1,000 – $1,200 for a one-month supply

Some insurance plans and other programs might reduce these costs. But the actual costs can get complicated, especially for off-label uses.

For example, Medicare currently covers Ozempic for use as a diabetes treatment but not for weight loss. That is expected to change in early 2027 after the federal government’s announcement about price cuts for Medicare recipients on 15 prescription drugs. Ozempic and Wegovy are on the list as an effort to reduce obesity.

Wegovy vs. Ozempic dosage

The dosage of the pre-filled single-use injections are another difference between Wegovy and Ozempic.

Wegovy dosage and method

• Wegovy is usually injected with a pre-filled, single-use pen at 0.25 mg, increasing on a set schedule to the maximum injection dosage of 2.4 mg.
• After four weeks, doctors may increase the dosage to 0.5 mg on weeks 5 – 8, 1.0 mg on weeks 9 – 12, 1.7 mg on weeks 13 – 16 and 2.4 mg on week 17 and every week after.

Ozempic dosage and method

• Ozempic is usually injected with a pre-filled single-use pen at 0.25 mg – 2 mg per injection.
• Treatment may continue with doctors increasing the dosage by 0.5 mg each week. The dosage maximum is 2.0 mg.

Wegovy and Ozempic share many characteristics. Here’s a closer look at the similarities between these semaglutide drugs.

Semaglutide as active ingredient

Semaglutide is the active ingredient in both Ozempic and Wegovy. This ingredient is a glucagon-like peptide-1 agonist that mimics the naturally occurring GLP-1 hormone to regulate glucose levels. It is approved for use (in different drugs) for long-term weight management or type 2 diabetes.

Semaglutide medicines regulate blood sugar levels and reduce appetite. When you eat, semaglutide slows digestion rates. It interacts with the receptors in your brain that signal fullness for longer periods. It also suppresses your hunger, so you consume less food and fewer calories.

Together, these effects often lead to weight loss while taking semaglutide.

How patients use semaglutide

Both Wegovy and Ozempic require weekly injections using a pre-filled disposable pen. Rybelsus® — another semaglutide drug — uses a daily oral tablet instead of a weekly injection.

Both Ozempic and Wegovy labels recommend starting with 0.25 mg doses, which may increase over time. Patients can inject Wegovy or Ozempic into their upper arm, abdomen or thigh. Drug makers recommend taking the drugs on the same day each week, with or without meals. It’s not required to take semaglutide injection at the same time of day.

Side effects shared by Ozempic and Wegovy

The common side effects of Ozempic or Wegovy can include diarrhea, nausea, vomiting and constipation. More serious side effects on the drugs’ labels include acute pancreatitis, acute kidney injury, bile duct blockages and gallstone attacks.

However, the Wegovy and Ozempic warning labels don’t include several concerning side effects. Patients taking these semaglutide medications have reported:

• Deep vein thrombosis (DVT)
• Gallbladder disease
• Gastrointestinal issues, including paralyzed stomach (gastroparesis) and gastroenteritis
• Ileus
• Intestinal blockages
• Necrotizing pancreatitis
• Pulmonary aspiration
• Vision loss and vision changes, including an eye-rotting injury called NAION

All of these are among the nearly 62,000 FDA adverse event reports for semaglutide drugs. Some of these adverse reactions may have long-term implications even after stopping the drug.

The FDA Adverse Event Monitoring System (AEMS) is intended to help identify safety concerns related to marketed products, but it doesn’t prove any product or drug is linked to or caused a particular side effect or injury. Reports by themselves aren’t an indicator of a drug’s safety profile. In addition, AEMS may include duplicate reports or may significantly undercount injuries.

Motley Rice lawyers have advocated for thousands of individuals who suffer serious injuries and medical conditions as a result of dangerous over-the-counter (OTC) and prescription medication.

If you suspect your use of prescription Wegovy or Ozempic may be responsible for your intestinal blockages, gastroparesis or the death of someone you love, do not hesitate to contact our legal team to discuss your options. We may be able to help by:

• Gathering valuable evidence to prove the manufacturers’ failure to warn
• Investigating whether Ozempic or Wegovy is responsible for your symptoms
• Demonstrating how Novo Nordisk may have failed to comply with FDA regulations
• Identifying potential problems that could impact your case

Learn more about our medical drug experience here.

Do not stop taking a prescribed medication without first consulting with your doctor. Discontinuing a prescribed medication without your doctor's advice can result in injury or death.

Ozempic, Wegovy, Mounjaro, Rybelsus and Zepbound remain approved by the U.S. Food and Drug Administration (FDA).